Moinova et al. previously reported that de novo methylation of the vimentin gene (mVIM) is a highly sensitive biomarker for BE, detectable in approximately 90% of BE patient biopsies, suggesting its potential as a screening tool [142]. Here, VIM is linked to Barrett esophagus.